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The Rise in the Prevalence of 




Nonalcoholic fatty liver disease (NAFLD) affects a third of the world’s population 
and its rapid rise parallels the increase in hepatocellular carcinoma (HCC). NAFLD 
replacing hepatitis C virus (HCV) infection as a leading indicator for liver transplan-
tation (LT) in the United States. NAFLD is a spectrum of disease ranging from simple 
steatosis (NAFL) to nonalcoholic steatohepatitis (NASH), which can progress to 
advanced fibrosis (AF) and cirrhosis, culminating in HCC. The main clinical concern 
of public health administrators is that many patients who are unaware of NAFLD 
remain undiagnosed and risk developing end-stage liver disease (ESLD). Clinicians 
overly rely on surrogate liver enzymes to identify patients with NAFLD, allowing for 
substantial liver disease to go unnoticed and untreated. Furthermore, according to 
epidemiological studies, in patients diagnosed with NAFLD, ethnicity plays a role 
in complications and treatment response, and ethnic correlations with NAFLD are 
thoroughly underreported. Although liver biopsy is the gold standard method for 
appropriately diagnosing and staging NAFLD, most patients can be effectively diag-
nosed non-invasively with imaging modalities and integrated tests that are routinely 
available in the clinic today. This chapter discusses the current global rise in the rates 
of NAFLD and HCC; the current key findings incidences and the recommended diag-
nostic approaches and in therapeutic methods.
Keywords: obesity, cirrhosis, hepatocellular carcinoma (HCC), insulin resistance 
(IR), liver transplantation (LT), metabolic syndrome (MetS), nonalcoholic fatty liver 
disease (NAFLD), nonalcoholic steatohepatitis (NASH)
1. Introduction
The liver is a 1.5 kg reddish-brown biochemical processing plant of immense 
responsibilities that include protein synthesis, xenobiotic or drug metabolism, blood 
detoxification, and the release of bile acids for digestion. In short, the liver plays a 
key role in the hemostasis of the body by regulating the levels of sugar, protein, and 
fat that circulate in the blood. However, obesity, which must be carefully defined 
according to ethnic-specific BMI cut-off points, may alter normal liver physiology 
and lead to liver disease [1]. Obesity is at the intersection of the chronic liver disease 
pathway that includes diabetes, metabolic syndrome (MetS), nonalcoholic fatty liver 
disease (NAFLD), and hepatocellular carcinoma (HCC). The complex association 
between obesity and liver function involving NAFLD, HCC, histopathology, and 
genetic factors is the subject of several collaborative research investigations [2–7].
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Over the past few decades, dramatic changes in lifestyle behaviors and health 
priorities have contributed to a significant rise in noncommunicable diseases such 
as obesity and NAFLD. Obesity is highly prevalent in the United States of America, 
estimated to represent between 30 and 38% of adults with a body mass index (BMI) 
greater than 30 kg/m2 [8, 9]. Obesity is also a risk factor for metabolic syndrome 
(MetS), which increases hepatic triglyceride (TGs) depositions. NAFLD is the most 
common cause of impaired liver function in Western countries, affecting over one 
quarter of the population [10, 11]. Obesity is driving the rise of NAFLD and nonal-
coholic steatohepatitis (NASH), the culmination of the fatty liver disease spectrum 
that is manifested by ballooning, scarring, cirrhosis, and finally liver failure and 
HCC [12]. It is estimated that globally the prevalence of NAFLD in the general 
population is 24–30% [13, 14]. Accounting for errors in accuracy that may exist 
in indirect measurement methodologies, in the United States, the prevalence of 
NAFLD in adults has risen from 18% in 1988–1991, to 29% in 1999–2000, to 31% in 
2011–2012 [15]. However, the prevalence of NAFLD in the United States diagnosed 
by ultrasonography alone was estimated to be 24.13% (95% CI 19.73–29.15%) [16].
1.1 NAFLD definition
Nonalcoholic fatty liver disease (NAFLD) is a broad-spectrum disease ranging 
from fat infiltration of hepatocytes with no symptoms (simple steatosis aka nonal-
coholic fatty liver, NAFL) to excess intrahepatic macroglobular and macrovesicular 
fat accumulation (5–10% by weight of liver) with aggravated inflammation (steato-
hepatitis aka nonalcoholic steatohepatitis, NASH) in the presence of little ethanol 
(typically <30 g per day for men and <20 g per day for women) or no alcohol con-
sumption in the last 12 months [12, 17]. It should be noted, however, there is now 
convincing evidence demonstrating that even “safe” levels of alcohol consumption 
are associated with adverse health outcomes [17–20] suggesting that future stud-
ies should include only nondrinker individuals in the “NAFLD definition” [21]. 
Therefore, for NAFLD classification, the patient must show evidence of hepatic fat 
accumulation in the absence of declared chronic alcohol consumption, or drug use 
that can induce steatosis, or hereditary disorders. This NAFLD designation excludes 
both macrovesicular and microvesicular steatosis encompassing certain drugs, 
toxins, viral hepatitis B (HBV), hepatitis C (HCV) or human immunodeficiency 
virus (HIV) infections, celiac disease, α-1 antitrypsin deficiency, hepatobiliary 
infectious diseases, hepatolenticular degeneration, hepatic malignancies, genetic 
hemochromatosis, Wilson’s disease, lipodystrophy, abetalipoproteinemia, Reye’s 
syndrome, HELLP syndrome, or decompensated cirrhosis, which may contribute 
to secondary causes of steatosis and elevated liver enzymes [22–24]. Additional 
medications targeted for exclusion are estrogen, sodium valproate, nonsteroidal 
anti-inflammatory drugs (NSAIDs), calcium antagonists, perhexiline-maleate, 
and antiretroviral drugs [25–27]. Appropriate medical history must also be taken 
to exclude the uncommon causes of fatty liver secondary to treatment with drugs 
such as amiodarone, diltiazem, steroids, synthetic estrogens, tamoxifen, and highly 
active antiretroviral therapy; refeeding syndrome and total parenteral nutrition; 
severe weight loss after jejunoileal or gastric bypass; lipodystrophy; and other rare 
disorders [28]. There are also strong opinions for the exclusion of “whole-body 
system diseases” such as inflammatory bowel syndrome, hypothyroidism, and 
lipoatrophy [25] from the “secondary fatty liver diseases” category because they 
may also induce liver steatosis.
NAFLD can be distinguished from alcoholic steatohepatitis (ASH) by the 
absence of alcohol consumption and on histological markers such as sclerosing 
hyaline necrosis, hepatocyte ballooning, portal granulocytic inflammation, lobular 
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inflammation, satellitosis, perisinusoidal fibrosis, Mallory-Denk bodies, and acute 
cholestasis among others [29–31]. However, it is important to note that NAFLD 
can also coexist with other liver diseases including HCV, hemochromatosis, and 
alcoholic liver disease, which can accelerate progression to end-stage liver disease 
(ESLD) [32].
1.2 The natural history of NAFLD
The pathophysiology of NAFLD and its variants is still incompletely understood 
thereby limiting the availability of effective diagnostic and therapeutic interven-
tion. The ongoing persistence of obesity and the accompanying high rates of 
diabetes will increase the prevalence of NAFLD [33]. In many cases, the natural 
cause of the disease is the development of cirrhosis and ESLD as the population 
ages. Increased mortality rates have been reported in studies that compared NAFLD 
patients with a normal reference population [34–36]. The primary cause of death 
for NAFLD patients is cardiovascular disease followed by nonliver cancer, whereas 
the third leading cause of mortality is liver-related complications including cir-
rhosis [33]. The exact prevalence of fatty liver condition is not known, but popula-
tion studies from the United States and China estimate that 28–30% of the general 
population has simple steatosis that carries a relatively benign prognosis and is 
measured using magnetic resonance spectroscopy (the most accurate imaging 
modality) and that 8% of the population has elevated alanine transaminase (ALT) 
[37, 38]. A follow-up of population-based studies examining the natural history of 
NAFLD patients in Minnesota revealed that 3.1% of the patients developed cirrho-
sis-related complications including ascites (2%), jaundice (2%), encephalopathy 
(2%), variceal bleeding (1%), and HCC (0.5%) [34]. Approximately 10–30% of 
those with steatosis develop NASH, and the development of NASH cirrhosis is 
associated with a poor long-term prognosis for 2.6% of them who will be at a risk 
of developing HCC [39–41]. Ten years following diagnosis, 45% will decompensate 
and the mortality rate for subjects with Child-Pugh A disease will be 20% [42]. 
Furthermore, besides having an increased liver-related mortality rate compared to 
the general population, patients with NASH also have an increased risk of cardio-
vascular death (15.5 vs. 7.5%, p = 0.04) [35]. Generally, NAFLD is a slowly progress-
ing disease, which does not culminate in ESLD in most patients. Identifying those 
who will develop a complete liver failure is a difficult proposition [43]. NAFLD data 
are limited on predictors of clinical progression to NASH and beyond. Due to the 
compounding effect of obesity, prospective longitudinal studies are needed to help 
in the prediction of outcomes for individual patients. On the other hand, patients 
with NASH have a worse prognosis and attempts should be made to include them in 
clinical trials of novel treatments for this condition. The sequence of steps in liver 
disease commencing with steatosis and eventually culminating in HCC (i.e., ESLD) 
is presented in Figure 1 [44].
1.3 NAFLD diagnosis and staging
The general classification of NAFLD as stated above and accepted by the 
American Association for the Study of Liver Diseases (AASLD) is a hepatic fat 
accumulation exceeding 5–10% by weight of the liver [45]. Accordingly, NAFLD 
diagnosis in the liver is based on: (i) the presence of simple steatosis, as determined 
by histological or imaging procedure; (ii) a total weekly consumption of less than 
140 g of ethanol for men and less than 70 g for women in the last 12 months; and 
(iii) the absence of competing etiologies for simple liver steatosis and the absence 
of coexisting causes for chronic liver disease [46]. An appropriate diagnosis of 
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NAFLD, which is multifaceted, requires that there is evidence of hepatic steatosis 
upon imaging and histology or both and that other causes of liver disease including 
steatosis have been excluded [23].
The increasing prevalence of obesity in the past few decades has led to a surge 
in NAFLD, which manifests liver cells as bloated with droplets of fat. It has been 
reported that 70% of centrally obese patients with diabetes and hypertension 
(HTN) harbor steatohepatitis on liver biopsy [47]. Imaging has enabled the obser-
vation of central obesity in 70–80% of these subjects and in 50–80% of patients 
with type 2 diabetes mellitus (T2DM). NAFLD is typically asymptomatic; there-
fore, diagnosis usually follows the subsidiary finding of abnormal liver enzymes 
or steatosis on imaging. Early diagnosis of NAFLD requires skilled and informed 
practitioners to halt fibrosis progression to more advanced stages. Liver needle 
puncture biopsy, although invasive, is the gold standard. Less-invasive methods of 
image detection tools may not provide consistent information due to the subjective 
interpretations of the data by radiologists [48]. But imaging tools such as abdominal 
ultrasound (US), computed tomography (CT), and magnetic resonance imaging 
(MRI) are beginning to meet this need. Ultrasound or sonography is very effective 
in diagnosing steatosis where greater than 33% of hepatocytes are steatotic but can 
be unreliable with lesser degrees of steatosis [49]. The other imaging modalities 
such as CT or MRI can also detect hepatic steatosis even though they are not used in 
the evaluation of steatosis. Currently, the combination of MRI and proton magnetic 
resonance spectroscopy (MRI/1H-MRS) is the most accurate noninvasive measuring 
tool of steatosis [50, 51]. 1H-MRS, which defines NAFLD as hepatic fat accumula-
tion (steatosis) >5% of total weight of the liver, is the most reliable quantitative tool. 
However, due to its prohibitive cost, it is not widely available. Ultrasonography, 
on the other hand, is the instrument of choice for most of the clinics due to its low 
cost and wide availability even though it is still relatively limited in the detection of 
inflammation, a more important and higher risk concern than steatosis for fibrosis, 
cirrhosis, and HCC [52, 53].
Controlled attenuation parameter (CAP), which is a novel ultrasound-based 
technique that assesses liver stiffness and steatosis simultaneously by employ-
ing transient elastography (TE) [54]. This CAP technique has been shown to 
accurately detect steatosis although its diagnostic threshold has not yet been 
determined. Obesity and diabetes are the main risk factors for NAFLD [55]. It has 
been reported that the presence of T2DM significantly increases the prevalence 
Figure 1. 
The progression and stages of NAFLD (adapted from Baranova et al., [44]). Steatosis is the initial NAFLD 
stage and is characterized by excessive accumulation of fat in hepatocytes. Subsequent inflammatory conditions 
accelerate the progression to NASH followed by liver cirrhosis, which may lead to HCC. Both steatosis and 
NASH can reverse to NAFLD.
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of NAFLD regardless of the diagnostic tool [56]. For example, using controlled 
attenuation parameter (CAP), the prevalence of NAFLD is estimated at 75% in 
T2DM population and 40% in the general population, whereas it is 65% and 
about 37% respectively when measured by 1H-MRS. The prevalence rate goes 
down when assessed by liver ultrasound, computed tomography, and plasma ALT 
in that order [56].
In contrast, most global population studies base their NAFLD characteriza-
tion on less sensitive and less specific surrogate markers of the disease including 
elevated liver-associated enzymes such as aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT >40 IU/L in males; >31 IU/L in females) [57, 
58]. Furthermore, serum ALT levels are within the range currently considered 
“normal” in a sizeable proportion of NAFLD subjects [59]. Typically, depending 
on the reference values from different laboratories, the broad range for normal 
AST is reported between 10 and 40 IU/L and ALT between 7 and 56 IU/L. This is 
because ALT usually falls (and AST may rise) as fibrosis progresses to cirrhosis. 
Mild elevations, which are generally asymptomatic, are considered to be 2–3 
times higher than the normal range, and drastic elevations are 5 times higher than 
the upper limit of normal, which varies according to gender [60]. Moreover, the 
very selective measurement of ALT level based on race or ethnicity underscores 
the lack of effective surrogate markers for NAFLD/NASH in the absence of biopsy 
[61]. Therefore, an innovative approach is needed to use metabolic risk factors 
to identify subjects with NAFLD/NASH rather than relying on liver enzyme 
abnormalities.
There is an active research that is underway to discover serum biomarkers for 
NASH since it is associated with increased apoptosis and therefore blood markers 
of apoptosis may be instrumental in distinguishing NASH from simple steatosis 
[62]. Apoptosis activates caspases that cleave various substrates such as cyto-
keratin-18 (CK-18), a key intermediate filament protein in hepatocytes, that can 
be detected with an ELISA test using an M30 antibody to identify patients with 
NASH [63, 64]. However, liver biopsy provides a superior assessment of hepatic 
steatosis, hepatocellular injury, inflammation, and fibrosis as well as its ability to 
demonstrate the presence of hepatocyte ballooning and degeneration in associa-
tion with steatosis as the key histological feature that distinguishes NASH from 
simple steatosis. Notwithstanding its limitations such as inherent variability in 
histologic assessment of NAFLD stage and activity, its invasiveness, its high pos-
sibility of complications related to liver damage, its proneness to sampling error 
generated by the operators, and its limitations in accessibility and reproduc-
ibility, liver biopsy is still the standard criterion for the most accurate diagnosis 
of NAFLD and NASH. Also, because only 7–30% of NAFLD patients in the world 
population had an indication of biopsy for accurate measurement, Younosis 
et al., re-evaluated and reported the global prevalence of NASH to be between 
1.5 and 6.45% and the North American rate at an average of 8.69% (between 7.2 
and 14.63%) [4, 65]. Regarding obesity, reports show that NASH can be veri-
fied by histological examination in about 47% of all NAFLD cases among obese 
individuals [66].
Liver fibrosis is the inordinate accretion of extracellular matrix proteins that 
include collagen in most types of liver disease including NAFLD. Fibrosis stage is a 
crucial histological variable to predict mortality. There are well-known independent 
predictors of fibrosis, which is a subway to chronic liver disease state. Some of these 
risk factors are age (>45–50), BMI (>28–30 kg/m2), insulin resistance (IR), diabe-
tes, and HTN [67]. Staging hepatic fibrosis is essential in all patients with NAFLD 
to identify individuals with advanced fibrosis (AF) who may later develop liver-
related complications such as hepatocellular dysfunction and portal hypertension 
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(PHTN). A noninvasive and an indirect assessment, which is performed in all liver 
disease patients including children, may include blood tests such as liver function 
tests (low albumin), complete blood count (thrombocytopenia and neutropenia), 
and coagulation profile (prolonged prothrombin time) [68]. Among the diagnostic 
tools used to measure the prevalence of AF in the setting of T2DM versus the 
general population, vibration-controlled transient elastography shows the highest 
prevalence rate followed by NAFLD fibrosis score and FibroTest in that order. It 
should be noted that the prevalence of T2DM significantly increases the prevalence 
of AF in similar ways to NAFLD [56].
The most widespread clinically implemented histological grading and staging 
system is the ‘NAFLD activity score’ (NAS) [6] (see Table 1). More recently, 
the SAF score encompassing an assessment of steatosis (S), activity (A), and 
fibrosis (F) has been used to produce more accurate measurements of NASH 
[5]. These recent developments underscore the fact that NAFLD patients can 
be diagnosed and staged effectively using noninvasive strategies even though 
liver biopsy can still be applied for individuals with dubious diagnostic tests or 
if noninvasive staging is unspecified [69]. However, there is no widely available 
simple blood test or imaging modality that can differentiate simple steatosis 
from NASH.
In summary, early diagnosis of NAFLD is essential to halting the progression 
of the disease. Biopsy is intrusive and therefore cannot be routinely applied. 
Ultrasound (sonography) and magnetic resonance imaging tools have become 
alternative noninvasive detection tools that can be routinely employed in clini-
cal practice. The NAFLD activity score is important as part of the diagnosis 
procedure. But the fibrosis score is just as important. Table 2 shows the fibrosis 
score currently used to stage the degree of fibrosis in the liver. There are a few 
noninvasive fibrosis imaging tests on the market such as Fibroscan that offers a 
liver stiffness measurement (LSM) using pulsed-echo ultrasound as a surrogate 
marker of fibrosis [70] and acoustic radiation force impulse (ARFI), which uses 
conventional B-mode ultrasonography to produce an ultrasonic pulse and measure 
the response of the liver tissue as shear wave velocity [71]. The Centers for Disease 
Control (CDC) and Prevention projects that diabetes mellitus is likely to impact 
the fibrosis progression rates, given the close link between diabetes and fibrosis in 
those with NAFLD [72, 73].
Some commercial biomarker tests include enhanced liver fibrosis (ELF), a panel 
of markers of matrix turnover as tissue inhibitor of matrix metalloproteinase 1 
(TIMP1), hyaluronic acid and PIIINP [74] and FibroTest (FT), a panel of markers 
of fibrosis widely used in France.
Grade Steatosis 
(%)
S score Lobular (L) 
inflammation




0 <5 0 No foci 0 None 0
1 5–33 1 <2 foci per 200 × field 1 Few cells 1
2 34–66 2 2–4 foci per 200 × filed 2 Many cells 2
3 >66 3 >4 foci per 200 × filed 3 N/A N/A
NASH activity grade = total score: S  +  L  +  B range (0–8). Score of ≥5 is equivalent to NASH; score of 3 or 4 is 
borderline NASH; score of ≤2 denotes non-NASH NAFLD. The NAFLD activity score is based on three pathologic 
features: Steatosis, hepatocyte ballooning degeneration, and lobular inflammation. Higher scoring denotes severity of 
NASH: >5 = NASH; <5 = No NASH; 3–4 = borderline; none (0); few (1); many (2).
Table 1. 
NAFLD activity score (NAS).
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1.4 The metabolic syndrome (MetS)
Recognizing patients with the metabolic syndrome (MetS) is key to identifying 
patients at risk of NAFLD. MetS is a group of risk factors that raises risk of heart 
disease, diabetes, stroke, etc. [75] and is diagnosed when any three of the following 
five clinical risk factors are present [76]: impaired fasting serum glucose, low levels 
of serum HDL cholesterol, elevated serum triglycerides (i.e., hypertriglyceridemia), 
central obesity or larger than cut-off waist circumference (varies according to 
gender and ethnicity), and high blood pressure (HTN) (see Table 3).
Insulin resistance is also a major risk factor for the development of steatosis. 
Once considered benign, NAFL (or simple steatosis), which is defined as the 
presence of hepatic steatosis with no evidence of hepatocellular injury in the form 
of ballooning of the hepatocytes, is now believed to be a serious risk factor for 
progression to liver disease, cardiovascular disease, and mortality [37, 77]. This is 
because an excess of abdominal fat is most tightly associated with the metabolic 
risk factors [78, 79]. The duration of obesity and the presence of MetS in an indi-
vidual patient are closely tied to the risk of developing NASH-related cirrhosis and 
HCC [80]. Some of the characteristics of MetS are present in most NAFLD indi-
viduals, with 65–71% being obese, 57–68% having deranged lipid profiles, 36–70% 
suffering from HTN, and 12–37% having impaired fasting glucose tolerance [81]. 
Approximately a third of patients with NAFLD have the full metabolic syndrome 
and >90% have at least one feature [47]. There is a consensus that considers 
NAFLD as a hepatic manifestation of the MetS [82, 83]. On the other hand, clinical 
signs of the disease are manifested in 70–75% of T2DM patients and up to 95% 
of obese patients [84]. Thus, the development of the MetS, which is an important 
Liver injury Fibrosis score (0–4)* Fibrosis stage
None 0 0
Mild (delicate fibrosis)/zone 3 presinusoidal fibrosis <5% (0), 5–33% = (1) 1a
Moderate (dense fibrosis)/zone 3 presinusoidal fibrosis >33–66% (2), >66% = (3) 1b
Periportal/portal fibrosis 0 (0), <2 (1), 2–4 (2), > (3) 1c
Portal and periportal fibrosis/presinusoidal fibrosis None (0) 2
Bridging fibrosis Few (1) 3
Cirrhosis Many (2) 4
*Fibrosis score of F1-F4 is generally considered NASH [4].
Table 2. 
NAFLD fibrosis score (NFS) and stage.
Features Terms of condition
Blood glucose (sugar) Fasting, ≥100 mg/dL
Blood HDL (“good”) cholesterol ♂ < 40 mg/dL; ♀ < 50 mg/dL
Blood triglycerides (TGs) Fasting, ≥150 mg/dL
Waist circumference ♂ > 40″; ♀ > 35″
Blood pressure (HTN) ≥130/85 mm Hg
*The MetS is present with any three of the features shown in the table.
♂ = male; ♀ = female; HDL = high-density lipoprotein; ″ = inches.
Table 3. 
Features of the metabolic syndrome.*
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predictor of NASH in NAFLD patients, poses a sweeping and unfavorable progno-
sis [85]. IR is a key mediator that links NAFLD and MetS, which is a constellation 
of anthropometric and metabolic abnormalities (see Table 3 above).
According to the latest data from NHANES (National Health and Nutrition 
Examination Survey) study conducted between 2011 and 2012, the prevalence of 
MetS has increased to 35% in American adults [86]. MetS is a risk factor for diabe-
tes and cardiovascular diseases. It induces an abnormal production of hormones 
such as leptin, adiponectin, and cytokines such as TNF (tumor necrosis factor)-
alpha that regulate inflammatory responses and cause disequilibrium between 
the pro-inflammatory and anti-inflammatory state of the organ [86]. These are 
mutually antagonistic: the pro-inflammatory factors such as TNF-alpha promote 
pro-apoptotic processes, recruit white blood cells, and promote insulin resistance. 
On the other hand, adiponectin acting as an anti-inflammatory factor inhibits 
fatty acid uptake, stimulates fatty acid oxidation and lipid export, and enhances 
insulin sensitivity. Both an increase in pro-inflammatory factors and a decrease in 
anti-inflammatory factors cause a cytokine imbalance that would lead to steatosis 
(NAFL) followed by necroinflammation (NASH) and IR. There is a supporting 
evidence that a high TNF to adiponectin ratio promotes fatty liver and steatohepa-
titis in animal [87] and human [88] studies. The importance of MetS including IR 
is that it predicts the occurrence of diabetes and cardiovascular diseases, which 
can further promote the development and progression of arteriosclerosis and HTN 
leading to significant morbidity and mortality [89]. Also, NAFLD and obesity are 
risk factors for the progression to fibrosis among HCV-infected patients [90–93]. 
Furthermore, elevated levels of ferritin are common in NAFLD patients and typi-
cally reflect active IR or underlying inflammatory activity [68, 81, 94]. Therefore, 
because of many different correlates and etiological factors and an assortment of 
assessment tools associated with MetS, there are some unresolved uncertainties in 
the current estimates of the global and the United States prevalence of NAFLD.
1.5 The genetics of NAFLD
Genetic disorders of lipid metabolism can cause hepatic fat deposition. However, 
they are far less common than excess body weight and features of MetS as risk fac-
tors for NAFLD and NASH. Several genes have been associated with NAFLD. These 
include NCAN, which may have a protective effect for Hispanics but increases risk 
of steatosis for non-Hispanic blacks; LYPLAL1, GCKR, as well as PPP1R3B, which 
may confer increased risk for hepatic steatosis but the data of distinctive serum 
lipid profiles in all these genes are sparse [61, 95–97]. GCKR is reported to be closely 
associated with NAFLD in Chinese [98]. Another gene, Patatin-like phospholipase 
domain-containing 3 (PNPLA3 or adiponutrin), has emerged as the genetic factor 
predisposing Hispanics more at risk for fatty liver disease [99]. This adiponutrin 
gene is a single variant considered responsible for increased hepatic TG levels, 
fibrosis, and inflammation, observed among ethnic groups [100, 101]. Homozygote 
patients have a twofold rise in hepatic fat content than heterozygotes, and Hispanic 
populations exhibit the highest frequency of this polymorphism (49%) compared 
to 23% in European-Americans (EAs) and 17% in African-Americans (AAs) [101]. 
It also shows more allelic frequency with Hispanics than other ethnic groups. 
Romeo and colleagues [102, 103] along with Singal and colleagues published papers 
in 2008 in which they reported that PNPLA3 is strongly associated with hepatic 
steatosis and elevated ALT and also recently showed that PNPLA3 is associated with 
NASH, fibrosis progression, and hepatocellular cancer as well [102].
A genetic marker, TM6SF2, discovered in an exome-wide association study of 
liver fat content, has also shed some light on its association with hepatic steatosis. It 
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is involved in the loss of function mutation in very low-density lipoprotein (VLDL) 
secretion, and its association with NASH and advanced fibrosis has been recently 
validated even though its precise function has not been delineated [102]. However, 
its mutation is associated with elevated ALT, hepatic steatosis, and lower level 
of alkaline phosphatase, LDL, and TGs. This gene is most prevalent in European 
ancestry and less in Hispanics and AAs [104].
There is a reported 52% heritability rate of NAFLD, but evidence pertaining 
to specific genetic mutations is scant according to multivariable models used 
after adjusting for sex, age, and ethnicity [13]. Although the mechanism is not 
well understood, genetic mutations in hemochromatosis (HFE) gene, which is 
responsible for iron uptake and transferrin plasma concentration, may also be 
associated with NAFLD development [105, 106]. Several other factors have been 
indicated in the development and outcomes of NAFLD including epigenetic 
alterations [107, 108], maternal perinatal nutrition [109–111], and gut microbiota 
[107, 112–114]. A recent study also reports a novel pathway in which hepatic 
vitamin D receptor (VDR) expression is increased in patients with simple 
steatosis (nonalcoholic fatty liver without inflammation), and the activated VDR 
upregulates angiopoietin-like protein 8 (ANGPTL8) expression, thus contribut-
ing to triglyceride accumulation in human hepatocytes [115]. At any rate, studies 
have reported that fibrosis-initiated fatty liver disease progresses over many 
years, thus providing a potential window for intervention by examining disease-
progression/modifying factors in NAFLD [116–118]. It is important to note that 
increased BMI and insulin resistance have been associated with a more rapid 
progression to fibrosis [35, 119].
1.6 The epidemiology and prevalence of NAFLD
In most epidemiological studies, the prevalence of NAFLD in the general 
population is determined by imaging or other indirect methods. Accordingly, the 
epidemiology and demographic characteristics of NAFLD vary worldwide [12, 16]. 
In epidemiological studies, the pathophysiological aspects, the natural history, and 
the determinants of NAFLD are important parameters for the diagnosis and evalu-
ation of therapeutic interventions. This section will provide global perspectives on 
the prevalence of NAFLD (and later HCC) with emphasis on the United States and 
the possible reasons for the rapid rise.
There are wide-ranging estimates of NAFLD prevalence in the general popula-
tion of the United States. An estimated 17–51% of adults have NAFLD [23, 120, 121].  
Analysis of liver ultrasound data collected between 1988 and 1994 from the 
NHANES III reported that 19% of adults have NAFLD [122], whereas a meta-anal-
ysis of studies from 2006 to 2014 estimated a NAFLD prevalence of 24% (20–29%) 
in the general population [65]. The prevalence of NASH is difficult to estimate as 
biopsy is the necessary tool for screening, but it is cost-prohibitive and impractical 
for a population study.
Globally, NAFLD is a growing cause of chronic liver disease and NASH is replac-
ing HCV infection as the primary reason for LT [13, 123, 124]. The broad category 
of NAFLD can manifest as NAFL or NASH. Fibrosis precedes cirrhosis and is 
therefore used as a prognosticator of the clinical risk of progression to cirrhosis and 
long-term liver-related adverse outcomes and mortality [34]. Recent evidence has 
shown that NAFLD and NASH can progress to HCC even in the absence of cirrhosis 
[125–127]. In most epidemiological studies including the NHANES data set, the 
assumptions about NASH in the NAFLD population are based on a post-hoc appli-
cation of liver enzymes (i.e., AST and ALT) and clinical measurements. In the same 
vein, the fibrosis stages in population-based studies reflect best estimates derived 
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from clinical aids (e.g., fibrosis-4, ALT to platelet ratio index, and NAFLD fibrosis 
scores) [128, 129]. The current prevalence rates for NAFLD, NASH, and HCC based 
on definitive clinical manifestations are shown in Table 4.
Certain risk factors such as advanced age, obesity, ethnicity, and T2DM increase 
the incidence and prevalence of NAFLD and NASH and have been consistently iden-
tified as salient risk factors for fibrotic progression to cirrhosis [130] (see Table 5).
The current global estimate is that 24–30% of the world’s population is affected 
by NAFLD [65] and that includes between 80 and 100 million Americans (http://
www.mayoclinic.com), making it the primary etiology for liver disease in the 
United States; see Figure 2.
The increasing incidence of obesity, diabetes, and metabolic syndrome in the 
United States and Europe may soon catapult NAFLD/NASH to become the most 
common cause of HCC in developed countries. In the United States, among the 
more than 26 million people with diabetes, the prevalence of biopsy-proven NAFLD 
and NASH is as high as 74 and 11%, respectively [138, 139].
1.7 The rise in burden of NAFLD/NASH
The global rise of NAFLD has exasperated the looming healthcare burden of 
disease. It may be difficult to accurately forecast the current and future burden of 
a disease that is rapidly progressing. However, there are modeling techniques and 
approaches that incorporate real-world surveillance data for NAFLD and NASH 
incidences, which are growing causes of cirrhosis and HCC. As with many models, 
the utility of the model is linked to the validity of the inputs into the model. One 
of these modeling approaches is based on the premise that public awareness and 
Status Definition Prevalence Prognosis
NAFLD Spectrum of fatty liver disease 
with <140 g for men and 
< 70 g for women per week of 
alcohol consumption
Estimated at 24–30% 
of global population 
[13, 14, 16] and at least 
31% of US population 
(7)
—
NAFL >5% simple hepatic steatosis 
by weight of liver without 
evidence of hepatocellular 
injury (i.e., hepatocyte 
ballooning)
>80% of NAFLD 
patients
Low probability of progression 
to cirrhosis
NASH >5% hepatic steatosis 
by weight of liver with 
inflammation and 
hepatocellular injury with or 
without fibrosis
Confirmed histologically
Estimated at up to 
21–59% of patients 
with NAFLD
Estimated at 
1.5–6.45% of US 
general US population 
[40, 96, 122]




Presence of cirrhosis with 
current or past histologic 
evidence of steatosis
10–30% of patients 
with NASH
About 31% have liver 
decompensation over 8 years; 






Estimated at annual 
rate of 2.6–12.8%*
Progresses to end-stage liver 
disease
*The prevalence of NASH-HCC is not firmly established. Data in the table are the annual incidence rate of developing 
HCC in patients with NASH-related cirrhosis.
Table 4. 
Prevalence of NAFLD and its more progressive forms, NASH and HCC.
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government health policies will be able to eventually level off national obesity 
incidences and prevalence, which in return will level off NAFLD [4]. The inter-
pretation of the output of this and other models attempting to analyze the burden 
of NAFLD is constrained by the lack of accurate diagnosis of steatohepatitis with 
simple epidemiologic tools. Nevertheless, the proportion of individuals with NASH 
in the NAFLD population will probably continue to rise through the next 15 years 
based on the rising prevalence of diabetes mellitus [4].
Analyzing the cost and burden of disease with respect to NASH has several 
potential implications. First, it helps introduce strategies and treatment regimen 
that will stem its exponential rise in incidence and mortality rates; it will reduce the 
growing contribution of NASH to LT, which is expensive; and due to an oversup-
ply of decompensated cirrhosis, matching organ availability is rare, and insurance 
companies have exclusive policy of qualifying subjects with NASH-induced cirrho-
sis based on whether they have associated co-morbidities.
The epidemiology and demographic characteristics of NAFLD vary worldwide. 
The rise in NAFLD and NASH will balloon the number of patients with decompen-
sated cirrhosis and pose a major emotional and financial burden on subjects and 
Risk factor Description References
Age Risk increases with age [4, 40]
Gender More common in men
Higher risk of advanced fibrosis in women
[4, 96, 131, 132]
Genetics Patatin-like phospholipase domain-containing 3 gene [133]
MetS** 70–90% of patients have NAFLD
MetS is an independent predictor of fibrosis
[85, 95]
Ethnicity Elevated risk in Hispanics
Lower risk in blacks
[61]
Diet Elevated levels of cholesterol and saturated fats
High fructose intake, low carbohydrates
[89, 134–136]
OSA*** Increased risk of hepatic fibrosis [137]






Global picture of estimated prevalence of NAFLD and distribution of PNPLA3 genotypes adopted from Zobair 
Younossi [16]. PNPLA3 is presented as minor allele frequency in some areas (light blue section of the pie chart).
Nonalcoholic Fatty Liver Disease - An Update
12
Hepatitis B infection (HBV)
Hepatitis C infection (HCV)
Hepatitis D infection (HDV)
Alcohol (ethanol)









*Diagnosis of cirrhosis is based on the presence of the ICD-9 codes for cirrhosis or complications of cirrhosis 
(gastroesophageal varices, encephalopathy, and nonmalignant ascites) recorded at least twice in any inpatient or 
outpatient encounter.
Table 6. 
Common risk factors for hepatocellular carcinoma.
their caregivers, thus adding to the overall cost of health care. Furthermore, the 
main etiologic factor adding to the burden of HCC is NAFLD [4]. In select NASH-
related HCC patients, liver resection and transplantation provide potentially curative 
therapeutic options; however, these procedures place a significant burden to health-
care resources and utilization [140]. Currently, NASH-related HCC has replaced 
HCV-related HCC as the fastest growing indication for LT in HCC candidates.
2. Hepatocellular carcinoma (HCC)
Liver cancer, which has limited therapeutic choices, has the second highest mor-
tality rate in the world [141]. HCC, which can lead to complications such as portal 
vein thrombosis (PVT), accounts for the majority of primary liver malignancies and 
is one of the leading causes of death in patients with advanced fibrosis or cirrhosis 
[141–144]. HCC can be caused by chronic infection with hepatitis B virus (HBV) 
or hepatitis C virus (HCV), alcohol abuse, as well as obesity and diabetes-induced 
MetS. NAFLD often occurs in the setting of metabolic disorders such as obesity and 
T2DM. These same metabolic conditions are also risk factors for NAFLD-associated 
HCC, which can materialize in individuals even in the absence of advanced fibrosis or 
cirrhosis. NASH-HCC appears to be phenotypically different from HCC arising from 
other chronic liver diseases (Table 6). By all accounts, the formation and progression 
of HCC are multistep processes. Therefore, the specific and detailed molecular events 
that underlie HCC development remain only partially understood [143].
2.1 The epidemiology and prevalence of HCC
Primary liver cancer in 2012 was identified as the second most common cause 
of cancer-related death in the world. In the United States, HCC is the most com-
mon histological subtype of liver cancer that accounts for 70–85% of primary 
liver malignancies [145, 146]. It is also the most rapidly rising cause of cancer and 
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cancer-related deaths with an incidence that has more than tripled over the last 
two decades. This high mortality reflects a poor prognosis and a poorer therapeutic 
intervention [147]. Compared to HCC caused by alcoholic liver disease and viral 
hepatitis, there is a lack of strong epidemiological data associated with the incidence 
and prevalence of HCC precipitating from NAFLD [140, 148]. While the prevalence 
of NAFLD is thought to be highest among Hispanics and Caucasians, the ethnic 
distribution among NAFLD-/NASH-related HCC patients has yet to be defined. 
Male patients are overrepresented in NASH-related HCC; however, gender has not 
been proven to be a statistical risk factor in NASH progression to HCC [7]. The ris-
ing incidence of NAFLD/NASH in the setting of obesity has led to a drastic growth 
in NASH-related HCC incidence [149]. Although NAFLD can present with HCC in 
the absence of NASH or cirrhosis, the cumulative annual incidence rate for develop-
ing HCC in patients with NASH-related cirrhosis is approximately 2.4–12.8% [125]. 
This suggests or utmost underlies that cirrhosis may be the main cause of HCC 
despite new emerging data suggesting that NAFLD may be an independent risk 
factor for HCC, even in the absence of cirrhosis [126, 150, 151].
There was also a twofold increase in the incidence of HCC in the United States 
over the past two decades, and it is projected to double over the next two decades. 
Compared to HCC in alcoholic liver disease and viral hepatitis, there is a lack of 
strong epidemiological data regarding the incidence and prevalence of HCC in 
NAFLD [148]. It is projected that in just 12 more years, HCC at its current pace 
of growth in the United States will outstrip breast and colorectal cancers as the 
third leading cause of cancer-related death. This is because the prevalence of HCC 
is expected to increase by 149% from 10,000 to 24,900 during 2015–2030, while 
the incidence of HCC cases is expected to increase from 5160 to 12,240 in 2030, 
an increase of 137% [4]. This alarming incidence is attributed to several different 
genetic and epigenetic alterations that are under investigation [4].
Modeling the epidemic of HCC suggests that in 2015, 3280 incident HCC cases were 
estimated to have progressed from compensated cirrhosis (64% of total), with the 
remaining 1880 incident cases occurring among ≤F3 (fibrosis score-3) cases [4]. By 
2030, 8790 incident HCC cases are predicted to occur among compensated cirrhotic 
cases or 72% of the annual incidence, reflecting aging and disease progression [4].
The true prevalence of NASH and NASH-related HCC is probably under-
estimated. This is because in 6.9–29% of HCC cases, the underlying etiology is 
unknown, further questioning the designation that the liver disease is secondary to 
cryptogenic cirrhosis [148]. Traits of NASH are more frequently observed in HCC 
patients with cryptogenic cirrhosis than in age- and sex-matched HCC patients 
of well-defined viral or alcoholic etiology [152]. In the past several years, myriad 
studies have tried to determine the variability of relationships between NAFLD/
NASH, cryptogenic cirrhosis, and HCC. In a recent meta-analysis, White et al. [125] 
estimated that 60% of HCC cases ascribed to NAFLD/NASH had cirrhosis either 
prior to diagnosis or at the time of diagnosis. This same analysis showed that NASH-
associated cirrhosis consistently manifested an increased HCC risk. Furthermore, 
the study also revealed that when compared to those with chronic HCV, the risk of 
developing HCC is lower in patients with cirrhosis due to NAFLD/NASH (HCV, 
19.7% vs. NAFLD/NASH, 26.9%) [125]. Although the prevalence of NAFLD-/
NASH-related HCC is not well delineated, the growing incidence of obesity and 
diabetes suggests the impact of NAFLD-/NASH-related HCC will continue to grow.
2.2 The genetics of HCC
Genomic analyses promise to improve tumor characterization for the opti-
mization of precision or personalized medicine for patients with HCC. Recent 
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developments and molecular techniques have significantly improved our under-
standing of the pathogenesis of HCC and its complex genetic landscape [153–156]. 
The integration of several profiling data from various sources may provide 
additional insight into the molecular mechanisms of HCC [153]. The first large-
scale multiplatform analysis of HCC conducted as part of The Cancer Genome 
Atlas (TCGA) network included valuation of somatic mutations by whole exome 
sequencing and DNA copy number analyses in 363 patients whose tissue and 
tumor specimens were obtained [157]. This high-throughput analysis also included 
further investigation of DNA methylation, mRNA expression, microRNA (miRNA) 
expression, and proteomic expression in 196 patients. To decipher the molecular 
landscape of HCC and extract biological insights for therapeutic targets and 
prognostic implications, analyses were made by integrating multiple data platforms 
with the available clinical data for HCC [157]. Mutational and DNA sequencing 
analyses identified an array of genes altered either by downregulation or by muta-
tion. Among the significantly mutated genes were EEF1A1, SMARCA4, LZTR1, 
and SF3B1 [157]. Those genes downregulated by hypermethylation including ALB, 
APOB, and CPS1 may cause metabolic reprogramming in HCC. The analysis of 
integrated molecular platform also yielded the identification of a subtype linked 
to poorer prognosis in three HCC cohorts. This large-scale multiplatform, high-
throughput analysis enabled the design of a p53 target gene expression signature 
correlating with poor survival. This TCGA network analysis produced potential 
therapeutic targets including WNT signaling, IDH1, MET, VEGFA, MCL1, MDM4, 
TERT, and immune checkpoint proteins PD-1, PD-L1, and CTLA-4 [157]. This is 
significant because effective inhibitors already exit for these targets, which alter 
hepatocyte energy balance [157].
In exome sequencing analysis of over 200 liver tumors, investigators identi-
fied mutational signatures that are associated with specific risk factors such 
as alcohol and tobacco consumption and exposure to aflatoxin B1 [158]. As a 
result, they found that 161 putative driver genes were associated with 11 recur-
rently altered pathways involving CTNNB1 (alcohol), TP53 (hepatitis B virus, 
HBV), and AXIN1 [158]. Further analysis of tumor stage progression identified 
TERT as an early event, whereas FGF3, FGF4, FGF19, or CCND1 amplification 
and TP53 and CDKN2A alterations were prominent in aggressive tumors. The 
involvement of these many altered genes and pathways in the development and/
or progression of HCC leads to the extensive landscape and multifaceted nature 
of this lethal cancer. Figure 3 shows the salient signaling pathways associated 
with HCC.
In another recent study, gene expression and DNA methylation profiles were 
screened to identify potential genetic biomarkers of HCC. The findings from this 
study suggest potential HCC biomarker roles for certain genes such as DTL, DUSP1, 
NFKBIA, and SOCS2 [160]. Similar to TCGA Research Network analyses mentioned 
above [157], these investigators also suggest that the tumor protein ‘p53 signaling’ 
and ‘metabolic’ pathways may serve important roles in the pathogenesis of HCC 
[160]. Other polymorphic variants serving as potential risk factors for HCC in high-
risk patients infected with HBV/HCV have also been reported [161]. As for prognos-
tic biomarkers, recent RNA sequencing data from the Cancer Genome Atlas (TCGA) 
reveal that among the 12 tissue types studied, the liver had the largest number of 
tissue-enriched genes, which are associated with the prognosis of patients with HCC 
and represent distinct physiological patterns [162]. A further study of the charac-
teristics of liver-enriched genes showed that hypermethylation might be partially 
responsible for the downregulation of these genes, most of which were metabolism-
related genes associated with pathological stage and dedifferentiation in patients 
with HCC. The authors suggest that hypermethylation might be a mechanism 
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Figure 3. 
The most reported signaling pathways in HCC. Adapted from Birgani et al. [159].
Figure 4. 
Validation of liver-enriched genes and KEGG analysis. (A) an example of liver-enriched genes. SPP2 was 
exclusively expressed in the corresponding nontumor tissues of HCC. (B) Four-set Venn diagram showing 
the overlap of the liver-enriched genes derived from the TCGA and three other databases, including HPA, 
PaGenBase, and TiGER. (C) Significantly enriched KEGG pathways of 188 liver-enriched genes. −log10 
(adjusted p-value) was annotated on each bar of the KEGG pathway. Adapted from Binghua et al. [162].
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underlying the downregulation of these liver-enriched genes. When they overlapped 
the tissue-enriched and prognostic genes across cancer types, they found that, in 
HCC, 55% (84/188) of the liver-enriched genes were prognostic (see Figure 4).
Circulating regulatory nucleic acids like miRNA profiles can also reflect the 
pathogenic changes occurring in organs including the liver. Changes in miR-21, 
miR-122, and miR-223 were correlated with the histological status of the human 
liver and were specific for liver injury [163]. These miRNA levels were significantly 
higher in the serum of chronic hepatitis (i.e., HBV and HCV) and HCC patients 
compared to healthy controls [44]. Yet, the biological heterogeneity of HCC makes 
it difficult to clarify the key mechanisms of cancer initiation and progression, and 
thereby develop and implement effective therapies [164].
3. The projection of NAFLD and HCC
A recent Markov model was used to predict incidence of NAFLD and to forecast 
NAFLD disease progression in the United States. The model was based on historical 
and projected changes in adult prevalence of obesity and T2DM as well as national 
surveillance data for incidence of NAFLD-related HCC [4]. The report forecasts that 
prevalent NAFLD cases will increase to 21% (100.9 million) by 2030, while prevalent 
NASH cases will increase 63% from 16.5 million to 27.00 million cases [4]. Overall 
NAFLD prevalence among the adult population (aged ≥15 years) is projected at 33.5% 
in 2030, and the median age of the NAFLD population will increase from 50 (esti-
mated at 2015 level) to 55 years between 2015 and 2030 [4]. In 2015, approximately 
20% of NAFLD cases were classified as NASH and are expected to increase to 27% by 
2030, a reflection of both disease progression and an aging population. The estimated 
prevalence of NASH in adults living in the United States is 3–5% [6, 23, 121, 165] 
and is projected to increase by 63% from 16.5 million in 2015 to 27.00 million cases 
in 2030 [4]. This prevalence of NASH was calculated based on published estimates 
and modeling of fibrosis progression. It was assumed that up to 5% of NAFLD cases 
without NASH could be NASH regressors, with most NASH regressors still in F0 stage 
[4]. Similarly, the incidence of decompensated cirrhosis will surge by 168% to 105,430 
cases in 2030, while incidence of HCC will increase by 137% to 12,240 cases. Liver 
deaths are estimated to increase 178% to 78,300 deaths in 2030. During 2015–2030, 
there are projected to be nearly 800,000 excess liver deaths. The aging population, 
the continuing high rates of adult obesity, and T2DM will propel NAFLD-related liver 
disease and mortality in the United States. Immediate strategies are required to curtail 
new NAFLD cases and mitigate disease burden.
Currently, NAFLD is estimated to affect more than 80 million and up to 90 
million Americans, making it the most common etiology for liver disease in the 
United States [16, 65]. In the United Kingdom, NAFLD has now become the most 
common cause of abnormal liver function tests (LFTs) [166]. Although NAFLD has 
emerged as a serious disease in affluent Western economies, its global prevalence 
encompasses the Middle East (32%), South America (31%), Asia (27%), the United 
States (24%), Europe (23%), and Africa (14%) [167]. Because of the increasing 
incidence of obesity and diabetes around the world, NAFLD has become a global 
public health concern. The prevalence of NAFLD varies according to age, sex, and 
the methodology used to measure the condition in each geographical location [61]. 
Currently, NAFLD is the most prevalent liver disease observed in patients with 
obesity, diabetes, and metabolic syndrome (MetS), all of which can confer insulin 
resistance (IR) and are known risk factors for the development of HCC, a growing 
indicator of LT [45, 69]. While HCV infection has been the most common indica-
tion for liver transplants to date, NASH is surpassing it as obesity reaches historic 
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highs and new direct-acting antiviral (DAA) drugs are essentially curing hepatitis C 
[168]. Furthermore, with the continued decline in the prevalence of HCV infection, 
the proportion of NASH-HCC is anticipated to increase exponentially due to the 
growing epidemic of obesity and diabetes [140]. Currently, NASH-related HCC is 
the fastest growing indication for LT in HCC candidates [140]. NAFLD and NASH 
are a growing cause of cirrhosis and HCC.
Globally, Asia is leading the rise in NAFLD followed by the United States. 
Although our understanding of NAFLD is steadily evolving, it is not an isolated 
disease. It is commonly associated with the leading metabolic comorbidities such 
as obesity, MetS, T2DM, and dyslipidemia. The potential progression of NAFLD 
subtypes is from fibrosis to advanced fibrosis, ESLD, and HCC (Figure 1). As the 
incidence of obesity and concurrently diabetes and MetS continues to surge in 
Europe and the United States, NAFLD/NASH may become the most common cause 
of HCC in developed countries in the foreseeable future [169–171].
A 2002–2012 retrospective cohort study among adult patients revealed a four-
fold increase in patients undergoing LT for NASH-related HCC in contrast to only 
twofold increase in number of patients undergoing transplantation for HCV-related 
HCC. In the United States, about 6000–7000 liver transplants are performed 
annually, and the rapid increase in the percentage (44.9%) of obese individuals 
during a 14-year period (2000–2014) is expected to escalate to 55% the number of 
NASH patients awaiting LT by 2030 [172]. The increased morbidity and mortality, 
healthcare costs, and declining health-related quality of life associated with NAFLD 
require more in-depth analysis. Figure 5 depicts the proposed mechanisms that ties 
NAFLD/NASH and HCC.
4. Ethnic and gender differences in NAFLD and HCC
Although still not fully resolved, the prevalence of NAFLD in the United States 
can vary by ethnicity. Even in this context, there are several factors that could 
explain the reported ethnic disparities. These include access to health care, genetic 
factors, environmental factors, affliction with chronic diseases, and the presence 
of chronic diseases such as the MetS [61, 65, 173]. In this context, the prevalence of 
NAFLD is reported to be highest in Hispanic-Americans, followed by Americans 
of European descent and then African-Americans [40, 61, 65, 122, 173]. Several 
Figure 5. 
Risk factors and proposed mechanisms for NAFLD- and NASH-related HCC, which is multifactorial. 
Proposed pathogenic mechanisms include obesity, peripheral and hepatic IR from T2DM, increased hepatic 
lipid storage and lipotoxicity, genetic mutations, and intestinal microbiota dysregulation. HCC, hepatocellular 
carcinoma; EMT, epithelial to mesenchymal transition; NAFLD, nonalcoholic fatty liver disease; NASH, 
nonalcoholic steatohepatitis; FFA, free fatty acid; IGF, insulin-like growth factor; LPS, lipopolysaccharide; 
PNPLA3, patatin-like phospholipase domain-containing 3; TM6SF2, transmembrane 6 superfamily member 2. 
Adapted from Cholankeril [140].
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studies have shown a relative sparsity of NAFLD cases among individuals of African 
descent living in or coming from Africa or the Caribbean region. Although the 
prevalence of metabolic disease and obesity is high in Afro-Caribbean ethnic groups 
compared to Caucasian and Hispanic groups, the frequency of NAFLD/NASH 
is reported to be low [61, 174]. This discrepancy might be due to an actual low 
number rate or biases that include low-recognition and low-referral rates in these 
ethnic minorities [175], as Afro-Caribbean patients are categorically less likely to be 
referred to other tertiary hospitals [176].
There are also ethnic differences in the incidence of HCC in the United States 
(see Sherif et al. for a comprehensive review) [61]. Compared to European-
Americans (EAs), the incidence of HCC is higher in African-Americans (AAs) 
and is associated with more advanced tumor stage at diagnosis and lower survival 
rates overall. Assessment of changes in the levels of metabolites of samples strati-
fied by race was made using gas chromatography-mass spectrometry in selected 
ion monitoring mode to identify ethnically diverse biomarkers in HCC between 
EA and AAs [177]. Race-specific metabolites including alpha tocopherol for AA 
and EA combined, glycine for EA, and valine for AA exhibited better sensitivity 
and specificity than the standard serological marker for HCC, alpha-fetoprotein 
(AFP) that is widely used for the diagnosis of HCC [177–180]. It is hypothesized 
that there is a variation in HCC-associated epigenetic modifications between AAs 
and EAs. Thus, the identification of aberrant DNA methylation and differentially 
modulated miRNAs can be used to better understand the mechanisms of disparities 
in HCC between races. Also, identifying epigenetic markers for HCC in a specific 
population will enhance personalized medicine that targets specific therapeutic 
approaches [181, 182]. This also demands the gathering together of a highly inter-
disciplinary team of experts to investigate changes in both DNA methylation and 
miRNA expression patterns between tumor, cirrhotic, and normal liver tissues from 
AA and EA participants. Identifying molecular cancer gene drivers and mutations 
may 1 day become critical for precision oncology.
Most epidemiological studies document prevalence of individual diseases in 
selected tertiary hospital populations [183]. This widespread practice, particularly 
when imaging and liver enzyme tests are involved and when the patients may be 
asymptomatic in the early stage of diagnosis, leads to underestimation and under-
diagnosis of NAFLD. This is especially true for minority populations in whom the 
natural development and progression of NAFLD and NASH are understudied and 
underreported as reflected by the paucity of data in the literature. Furthermore, 
the predictive value of the MetS may not reflect the true state of NAFLD in AAs 
since the criteria for the syndrome were developed for non-Hispanic whites [184] 
thereby influencing underdiagnosis or misdiagnosis of NAFLD and NASH in 
Hispanics and non-Hispanic blacks (NHB). There is also a strong relationship 
between insulin resistance and hypertriglyceridemia, one of the crucial components 
of MetS. However, NHB often have normal triglycerides (TG) level [185], which is 
used as a diagnostic criterion of the MetS leading to underdiagnosis of the MetS in 
NHB [186]. This suggests that lowering the threshold for TG level in AAs will lead 
to grasping the true cases of NAFLD. Moreover, the racial differences in NAFLD 
and NASH may be a function of the differences in TGs or the differences in the 
distribution of adiposity (e.g., subcutaneous vs. visceral) since AAs have relatively 
less VAT and lower TGs than Hispanics [119, 173, 175]. In addition, AAs may be 
more resistant to both the accretion of TG in the abdominal visceral compartment 
(adipose tissue and liver) and hypertriglyceridemia associated with IR [119].
Epidemiologic studies establish the foundational framework for the control 
and prevention of diseases. In the case of NAFLD and NASH, it should be done by 
first tracking the prevalence of the disease, characterizing its natural history, and 
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identifying both its social and health determinants along ethnic lines. This type of 
study is critical for the proper diagnosis and early intervention of NAFLD especially 
in minority populations [61].
Genome-wide association studies have revealed several genetic variants that 
are associated with NAFLD and NASH. Yet, these variants either represent only a 
limited amount of variation in hepatic steatosis among ethnic groups or may just be 
markers representing a larger body of genetic variations.
There is an urgent need to gain a better understanding of the underlying biologi-
cal mechanisms responsible for why some people with NAFLD are more prone to 
developing HCC, and the causes for disparities in NAFLD-related HCC. There is 
also an urgent need for a less invasive method than biopsy and for a more sensitive 
biomarker than ALT for large-scale NAFLD screening. The lack of high-throughput 
studies employing proteomics or metabolomics for the discovery of novel and 
reliable diagnostic biomarkers for NAFLD also hampers our understanding of the 
pathophysiology of the disease among the disparate ethnicities [12, 177].
One recent area of exploration is the involvement of DNA methylation and 
miRNA regulation. Epigenetic alterations are potentially reversible, and this 
possibility will facilitate the development of biomarkers and therapeutics in the 
prevailing disparities between AA and EA patients in HCC initiation and develop-
ment. The identification and functional validation of race-specific methylation 
hotspots and miRNAs can be used to understand the mechanisms of disparities 
in HCC. This can be done by first identifying DNA methylation sites and miR-
NAs with statistically significant changes between HCC cases and cirrhotic or 
normal controls in a race-specific manner. Then, network-based methods and 
hierarchical integrative models can be used to integrate epigenomic data with 
transcriptomic, proteomic, glycoproteomic, and metabolomic data acquired 
from the same cirrhotic and HCC participants to select methylation hotspots and 
miRNAs relevant for understanding the mechanisms of disparities in HCC [177]. 
The selected candidates can then be validated by independent methods using 
frozen and formalin-fixed, paraffin-embedded (FFPE) liver tissues collected 
from patients with HCC and liver cirrhosis. Finally, functional validation of 
race-specific epigenetic modifications discovered in this type of high-throughput 
study can be performed through in vitro experiments using established cell lines 
derived from racially diverse populations. These cell cultures may present unique 
opportunities for targeted functional validation of epigenetic modifications and 
the downstream consequences.
In addition to exploring the external environment and how it influences HCC 
disease status, it is also necessary to explore the intestinal environment of different 
ethnicities. Experimental data from the obesity epidemic have revealed that the 
composition and products of the gut microbiome, which is altered with obesity and/
or a high fat diet, are carcinogenic to the liver [187, 188]. Studies suggest that there 
are ethnic differences in microbial composition in a cirrhotic population at elevated 
risk for HCC as a result of metabolites, which can differentiate cirrhotic with 
HCC from those without HCC. Therefore, a case-control study can be designed to 
examine the contributions of race/ethnicity, fecal microbiome, fecal metabolome, 
and host factors (e.g., specific dietary factors and markers of body and liver fat 
composition) to NAFLD-related HCC. All in all, a multiethnic study of NAFLD and 
HCC that encompasses all racial/ethnic groups is needed to lay the groundwork for 
the elucidation of factors that account for health disparities across these popula-
tions. The prevalence of NAFLD is reported to be highest among Hispanics and 
Caucasians as mentioned above. However, NASH was the leading cause of waitlist 
LT registration in 2016 among Asian, Hispanic, and non-Hispanic white females, 
whereas HCV is still the leading cause in AA females [189].
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As for gender differences in NAFLD or NASH, there are uncertainties includ-
ing the role of IR in the influence of gender on NAFLD. Ruhl et al. reported that 
NAFLD is about 2.7 times more prevalent in men than in women [190]. One reason-
able explanation for this reported gender difference in NAFLD is due to the higher 
waist-to-hip circumference (WHR) ratio in men [96]. Pan et al. further state that 
WHR is associated with visceral adipose tissue (VAT), which is correlated with both 
peripheral and hepatic IR. Similarly, in the Dallas Heart Study, European-American 
(EA) men had an approximately twofold higher prevalence of hepatic steatosis than 
EA women. This gender disparity has been blamed on alcohol use, sex hormones or 
lifestyle behaviors, and no differences in body weight or insulin sensitivity [96].
The ethnic distribution among NAFLD-/NASH-related HCC patients has yet 
to be defined [191]. If the increase in the number of ethnic groups waitlisted for 
LT from 2004 to 2016 is a good indicator of the rise in NASH-HCC, then it could 
be inferred from a recent retrospective study that Asian females had an 854% 
change in NASH waitlist registration, while Asian males had a 552% change [189]. 
The increase in African-American waitlist population was much less compared 
to the other ethnic groups. In contrast, the Hispanic females had a 3010% change 
in the rate of waitlist registration for NASH with HCC, while non-Hispanic white 
females had a 1992% change [189].
NASH-related HCC patients are primarily male even though gender is not a 
proven statistical risk factor in the progression of NASH to HCC. However, NASH is 
currently the second leading cause for LT waitlist in females, whereas in men, alco-
holic liver disease (ALD) continues to be the leading cause [189]. Although old data 
of 698 patients from biopsy-proven NASH show that NASH patients are more likely 
to be female than male possibly reflecting a higher disease burden rate in women 
[192], it is likely that both gender and racial ethnic differences in NAFLD and NASH 
are attributed to interaction among genetic, environmental, and lifestyle behaviors.
5. Medical therapy for NAFLD and HCC
The biological heterogeneities of NAFLD and HCC create predicaments in 
deciphering the key mechanisms of development and progression from NAFLD to 
ESLD. Although progress is being made in understanding the molecular underpin-
nings of chronic liver disease and its various offshoots, there are still formidable 
challenges in providing effective treatment regimens. Aside from a few prophylactic 
agents that have shown promise in the prevention and treatment of steatohepa-
titis and fibrosis, there is no treatment consensus due to scarcity of data [140]. 
Wholesome lifestyle and behavioral changes that include regular physical activity, 
low caloric intake, and weight loss are the main bulwarks against NAFLD, which 
may progress to HCC with or without cirrhosis. However, the extent to which 
these modifications are effective to prevent the development of HCC is unclear. 
There is currently no effective chemoprevention to decrease the incidence of HCC 
except using nucleoside analogs to reduce viral replication for those infected with 
HBV [193] and direct-acting antivirals (DAAs) for those infected with HCV [194], 
the latter demonstrating very high cure rates but also raising concerns about the 
recurrence or development of HCC after the achievement of a sustained virologi-
cal response [195]. Obeticholic acid (OCA), a selective agonist of the Farnesoid X 
receptors, was touted to be a promising pharmacological drug for the management 
of NAFLD. However, its low efficacy and specificity have dampened enthusiasm for 
its practical use. Also, the drug pioglitazone has no long-term impact on NASH. This 
entails a pressing need to develop more effective and safe agents for NAFLD and 
HCC. Several other experimental studies suggest a direct role for vitamin D in 
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modulating liver fibrosis and inflammation by enhancing hepatic response to 
insulin via binding to vitamin D receptor on liver cells [196–198]. Vitamin E and 
carotenoids are also shown to decrease plasma levels of patients with NASH [199], 
whereas dietary antioxidants such as vitamin C and coenzyme Q12, trace minerals 
such as selenium, anticholesterol medications such as statins, antidiabetic drugs 
such as metformin, and methyl radical donors such as S-adenosylmethionine have 
all been touted as potential prophylactic agents [169, 200–202].
6. Key findings, future trends, and unmet needs
Hepatic steatosis is associated with many other morbidities. Therefore, dissect-
ing the myriad causative agents including genetic, hormonal, or environmental 
factors underlying the pathogenicity of simple hepatic steatosis must be a priority to 
avoid the maze of complications that may arise during the development of NAFLD 
and its progression to HCC. The key findings are:
• Global prevalence of NAFLD is at 24% but is rising to greater than 30%; high-
est rates to lowest rates are found in South America, Middle East, Asia, United 
States, and Europe.
• The large volume of patients sets NAFLD apart from other liver diseases; thus, 
clinical care must focus on discerning highest risk of progressive liver disease.
• Overweight in childhood and adolescence is associated with the risk of NAFLD 
later in life and increases liver-related morbidity and/or mortality.
• NAFLD patients have an elevated risk of liver-related morbidity/mortality and 
metabolic comorbidities, which place a strain on healthcare systems.
• NAFLD warrants that primary-care physicians, specialists, and health policy-
makers stress prevention of excessive weight gain during childhood.
• Bariatric surgery may be an alternative option to committed weight loss.
• Older age, being male, and HA are independent risk factors for NAFLD/NASH.
• NAFLD is linked with higher BMI, higher HTN, and lower physical activity.
• MetS as currently defined is not a good predictor of NAFLD in non-Hispanic 
blacks (NHB); because in contrast to others, TG level is normal in this group.
• Proton magnetic resonance spectroscopy is currently the best proven alternative 
tool to biopsy for accurate diagnosis of NAFLD.
• Treatment options require more robust studies on etiology of NAFLD.
• There is no proven medical therapy for NASH.
• Most effective therapeutic strategies include lifestyle changes including diet, 
exercise, modifying metabolic risk factors, early screening, and intervention.
• Certain genes may be associated with disparities in lipid metabolism.
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• Alternative noninvasive markers of NASH may now be available even though 
there are no proven biomarkers for various stages of the NAFLD spectrum.
• Discovery of new biomolecules during clinical trials and metabolomics studies 
is crucial for understanding NAFLD/NASH initiation and progression.
• Patients with NASH have a worse prognosis and must be included in clinical 
trials of new treatments.
• The biological heterogeneity of HCC makes it difficult to assess the key mecha-
nisms of cancer development and thus implement effective therapies.
• Certain genes have been identified to be associated with progression to HCC.
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